Pyroxamide | whatman (沃特曼)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Pyroxamide 纯度: 99.73%

Pyroxamide 是一种有效的组蛋白脱乙酰基酶 1 (HDAC1) 抑制剂，ID₅₀ 为 100 nM。 Pyroxamide 可以诱导白血病细胞凋亡和细胞周期停滞。

Pyroxamide Chemical Structure

CAS No. : 382180-17-8

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥550	In-stock
5 mg	￥500	In-stock
10 mg	￥850	In-stock
25 mg	￥1800	In-stock
50 mg	￥3100	In-stock
100 mg	￥5400	In-stock
200 mg		询价
500 mg		询价

* Please select Quantity before adding items.

Pyroxamide 相关产品

•相关化合物库:

Clinical Compound Library Plus
Bioactive Compound Library Plus
Apoptosis Compound Library
Cell Cycle/DNA Damage Compound Library
Epigenetics Compound Library
Histone Modification Research Compound Library
Anti-Cancer Compound Library
Clinical Compound Library
Anti-Aging Compound Library
Reprogramming Compound Library
Oxygen Sensing Compound Library
Anti-Breast Cancer Compound Library
Anti-Pancreatic Cancer Compound Library
Anti-Blood Cancer Compound Library
Anti-Liver Cancer Compound Library

生物活性

Pyroxamide is a potent inhibitor of histone deacetylase 1 (HDAC1) with an ID₅₀ of 100 nM. Pyroxamide can induce apoptosis and cell cycle arrest in leukemia^[1].

IC₅₀ & Target

HDAC1

100 nM (ID₅₀)

体外研究
(In Vitro)

Pyroxamide (1.25-20.0 μM; 24-72 hours) suppresses RD and RH30B cells growth, pyroxamide resulted in 44% dead cells for 72 h at 20.0 μM, results in 86% dead cells in culture^[1].
Pyroxamide (10.0-20.0 μM; 48 hours) shows sub-G1 fractions of 45.0% and 72.3% at 10.0 and 20.0 μM, respectively^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	RD cells; RH30B cells
Concentration:	1.25-20.0 μM
Incubation Time:	24 hours; 48 hours; 72 hours
Result:	Resulted in a cell growth decrease in RD and RH30B cells.

Cell Cycle Analysis^[2]

Cell Line:	RD cells; RH30B cells
Concentration:	10.0 μM; 20.0 μM
Incubation Time:	48 hours
Result:	Increased the sub-G1 fractions at 48 hours compared with control samples.

Clinical Trial

分子量

265.31

Formula

C₁₃H₁₉N₃O₃

CAS 号

382180-17-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 125 mg/mL (471.15 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.7692 mL	18.8459 mL	37.6918 mL
5 mM	0.7538 mL	3.7692 mL	7.5384 mL
10 mM	0.3769 mL	1.8846 mL	3.7692 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.08 mg/mL (7.84 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (7.84 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (7.84 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (7.84 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.08 mg/mL (7.84 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (7.84 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Butler LM, et al. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res. 2001 Apr;7(4):962-70.

[2]. Kutko MC, et al. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.Clin Cancer Res. 2003 Nov 15;9(15):5749-55.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务